Health Equity in Biomarker Testing and Targeted Therapy
Cancer biomarker testing can lead to targeted therapy which can improve survival and quality of life by connecting patients to the most beneficial treatment for their disease.
Pharmacogenomic (PGx) testing (also known as pharmacogenomic biomarker testing) is a component of precision medicine that involves examining a patient’s inherited genes to detect variations that may impact the way a drug is broken down, absorbed and used within the body. Sometimes these variations can impact the safety and effectiveness of treatment. The same treatment given to patients with the same disease can produce different responses based on each person's inherited genes.